New Delhi: Drug firm Alembic Pharmaceuticals reported a 35.69 percent rise in its consolidated net profit to Rs 90.47 crore for the quarter ended June 30 on account of robust sales.
The company had posted a net profit after taxes, non-controlling interests and share of profit of associates and joint ventures of Rs 66.67 crore for the same period of the previous fiscal, Alembic Pharmaceuticals said in a BSE filing.
Consolidated revenue from operations of the company stood at Rs 862.53 crore for the quarter under consideration. It was Rs 648.19 crore for the corresponding period year ago.
Alembic Pharmaceuticals MD Pranav Amin said: “The robust performance in the quarter is attributed to growth across territories. This was led by India formulation business which was impacted by GST transition last year.”